MODIFIED BMI DOES NOT PREDICT ADVERSE OUTCOMES IN PATIENTS WITH CARDIAC AMYLOID UNDERGOING HEART TRANSPLANTATION: A REPORT FROM ICCAT (INTERNATIONAL CONSORTIUM FOR CARDIAC AMYLOID TRANSPLANTATION)

Abstract

Modified body mass index (mBMI), (BMI × serum albumin) predicts clinical outcomes after liver-transplant for transthyretin-related amyloidosis (ATTR). We sought to evaluate the utility of mBMI to predict outcomes in patients with cardiac amyloidosis undergoing orthotopic heart transplantation (OHT